Skip to main content
Erschienen in: Current Treatment Options in Oncology 6/2020

01.06.2020 | Skin Cancer (T Ito, Section Editor)

The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma

Epithelial-to-Mesenchymal Transition in Cutaneous SCC

verfasst von: Maria-Teresa Fernandez-Figueras, MD, PhD, Luis Puig, MD, PhD

Erschienen in: Current Treatment Options in Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Opinion statement

The capacity of cells to modify their phenotypes from epithelial to mesenchymal (epithelial-to-mesenchymal transition or EMT) and vice versa provides them with a dynamic plasticity essential for human life, from embryogenesis to wound healing. Current knowledge about carcinogenetic mechanisms leaves little doubts on the pivotal participation of these interchangeable processes in cancer development, and their influence has been quite clearly established in the progression of cutaneous squamous cell carcinoma. A complex and ordered interplay of signals induces the shift between both phenotypes, providing cells with the most suitable state at every moment to face the next step in tumor invasion and dissemination. Some stimulatory triggers have opposite effects according to the biological context and in many cases exert collateral functions. This scenario makes finding an ideal therapeutic target difficult but provides the opportunity to intervene simultaneously at many different levels with small actions such as targeting the tumor environment. In any case, advances in knowledge of the EMT mechanisms and their influence on carcinogenesis and drug resistance will greatly influence the therapeutic strategies for many human tumors, including cutaneous squamous cell carcinoma.
Literatur
1.
Zurück zum Zitat Bertrand K. Survival of exfoliated epithelial cells: a delicate balance between anoikis and apoptosis. J Biomed Biotechnol. 2011;2011:534139.PubMedPubMedCentral Bertrand K. Survival of exfoliated epithelial cells: a delicate balance between anoikis and apoptosis. J Biomed Biotechnol. 2011;2011:534139.PubMedPubMedCentral
3.
Zurück zum Zitat Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995;154:8–20.CrossRef Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995;154:8–20.CrossRef
7.
Zurück zum Zitat Song L, Tuan RS. Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. FASEB J. 2004;18:980–2.PubMedCrossRef Song L, Tuan RS. Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. FASEB J. 2004;18:980–2.PubMedCrossRef
8.
Zurück zum Zitat Block CJ, Dyson G, Campeanu IJ, Watza D, Ratnam M, Wu G. A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer. Sci Rep. 2019;9:17807.PubMedPubMedCentralCrossRef Block CJ, Dyson G, Campeanu IJ, Watza D, Ratnam M, Wu G. A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer. Sci Rep. 2019;9:17807.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Acloque H, Thiery JP, Nieto MA. The physiology and pathology of the EMT. Meeting on the epithelial–mesenchymal transition. EMBO Rep. 2008;9:322–6.PubMedPubMedCentralCrossRef Acloque H, Thiery JP, Nieto MA. The physiology and pathology of the EMT. Meeting on the epithelial–mesenchymal transition. EMBO Rep. 2008;9:322–6.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Stone RC, Pastar I, Ojeh N, Chen V, Liu S, Garzon KI, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res. 2016;365:495–506.PubMedPubMedCentralCrossRef Stone RC, Pastar I, Ojeh N, Chen V, Liu S, Garzon KI, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res. 2016;365:495–506.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Li X, Zhang Z, Zhang Y, Cao Y, Wei H, Wu Z. Upregulation of lactate-inducible snail protein suppresses oncogene-mediated senescence through p16INK4a inactivation. J Exp Clin Cancer Res. 2018;37:39.PubMedPubMedCentralCrossRef Li X, Zhang Z, Zhang Y, Cao Y, Wei H, Wu Z. Upregulation of lactate-inducible snail protein suppresses oncogene-mediated senescence through p16INK4a inactivation. J Exp Clin Cancer Res. 2018;37:39.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Polette M, Mestdagt M, Bindels S, Nawrocki-Raby B, Hunziker W, Foidart J-M, et al. Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs. 2007;185:61–5.PubMedCrossRef Polette M, Mestdagt M, Bindels S, Nawrocki-Raby B, Hunziker W, Foidart J-M, et al. Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs. 2007;185:61–5.PubMedCrossRef
16.
Zurück zum Zitat Murtas D, Maxia C, Diana A, Pilloni L, Corda C, Minerba L, et al. Role of epithelial-mesenchymal transition involved molecules in the progression of cutaneous melanoma. Histochem Cell Biol. 2017;148:639–49.PubMedCrossRef Murtas D, Maxia C, Diana A, Pilloni L, Corda C, Minerba L, et al. Role of epithelial-mesenchymal transition involved molecules in the progression of cutaneous melanoma. Histochem Cell Biol. 2017;148:639–49.PubMedCrossRef
17.
Zurück zum Zitat Li Z-R, Jiang Y, Hu J-Z, Chen Y, Liu Q-Z. SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1-mediated PI3K/AKT signaling pathway. Oncol Lett. 2019;17:1617–25.PubMed Li Z-R, Jiang Y, Hu J-Z, Chen Y, Liu Q-Z. SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1-mediated PI3K/AKT signaling pathway. Oncol Lett. 2019;17:1617–25.PubMed
18.
Zurück zum Zitat Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adhes Migr. 2015;9:317–24.CrossRef Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adhes Migr. 2015;9:317–24.CrossRef
19.
Zurück zum Zitat Nieszporek A, Skrzypek K, Adamek G, Majka M. Molecular mechanisms of epithelial to mesenchymal transition in tumor metastasis. Acta Biochim Pol. 2019;66:509–20.PubMed Nieszporek A, Skrzypek K, Adamek G, Majka M. Molecular mechanisms of epithelial to mesenchymal transition in tumor metastasis. Acta Biochim Pol. 2019;66:509–20.PubMed
22.
Zurück zum Zitat Yeo CD, Kang N, Choi SY, Kim BN, Park CK, Kim JW, et al. The role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: a possible link to epigenetic regulation. Korean J Intern Med. 2017;32:589–99.PubMedPubMedCentralCrossRef Yeo CD, Kang N, Choi SY, Kim BN, Park CK, Kim JW, et al. The role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: a possible link to epigenetic regulation. Korean J Intern Med. 2017;32:589–99.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Chaudhary S, Islam Z, Mishra V, Rawat S, Ashraf GM, Kolatkar PR. Sox2: a regulatory factor in tumorigenesis and metastasis. Curr Protein Pept Sci. 2019;20:495–504.PubMedCrossRef Chaudhary S, Islam Z, Mishra V, Rawat S, Ashraf GM, Kolatkar PR. Sox2: a regulatory factor in tumorigenesis and metastasis. Curr Protein Pept Sci. 2019;20:495–504.PubMedCrossRef
25.
Zurück zum Zitat Renganathan A, Felley-Bosco E. Long noncoding RNAs in cancer and therapeutic potential. Adv Exp Med Biol. 2017;1008:199–222.PubMedCrossRef Renganathan A, Felley-Bosco E. Long noncoding RNAs in cancer and therapeutic potential. Adv Exp Med Biol. 2017;1008:199–222.PubMedCrossRef
26.
Zurück zum Zitat Innao V, Allegra A, Pulvirenti N, Allegra AG, Musolino C. Therapeutic potential of antagomiRs in haematological and oncological neoplasms. Eur J Cancer Care (Engl). 2020:e13208. Innao V, Allegra A, Pulvirenti N, Allegra AG, Musolino C. Therapeutic potential of antagomiRs in haematological and oncological neoplasms. Eur J Cancer Care (Engl). 2020:e13208.
31.
Zurück zum Zitat Wang H, Unternaehrer JJ. Epithelial-mesenchymal transition and cancer stem cells: at the crossroads of differentiation and dedifferentiation. Dev Dyn. 2019;248:10–20.PubMedCrossRef Wang H, Unternaehrer JJ. Epithelial-mesenchymal transition and cancer stem cells: at the crossroads of differentiation and dedifferentiation. Dev Dyn. 2019;248:10–20.PubMedCrossRef
32.
Zurück zum Zitat Takaishi M, Tarutani M, Takeda J, Sano S. Mesenchymal to epithelial transition induced by reprogramming factors attenuates the malignancy of cancer cells. PLoS One. 2016;11:e0156904.PubMedPubMedCentralCrossRef Takaishi M, Tarutani M, Takeda J, Sano S. Mesenchymal to epithelial transition induced by reprogramming factors attenuates the malignancy of cancer cells. PLoS One. 2016;11:e0156904.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18:70.PubMedPubMedCentralCrossRef Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18:70.PubMedPubMedCentralCrossRef
35.
36.
Zurück zum Zitat Ferrari N, Ranftl R, Chicherova I, et al. Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nat Commun. 2019;10:130.PubMedPubMedCentralCrossRef Ferrari N, Ranftl R, Chicherova I, et al. Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nat Commun. 2019;10:130.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat •• Debaugnies M, Sánchez-Danés A, Rorive S, Raphaël M, Liagre M, Parent M-A, et al. YAP and TAZ are essential for basal and squamous cell carcinoma initiation. EMBO Rep. 2018. https://doi.org/10.15252/embr.201845809 Demonstrates the importance of YAP and TAZ on cancer initiation and specifically the role of YAP on epithelial-to-mesenchymal transition, suggesting that these can be targetable drugs. •• Debaugnies M, Sánchez-Danés A, Rorive S, Raphaël M, Liagre M, Parent M-A, et al. YAP and TAZ are essential for basal and squamous cell carcinoma initiation. EMBO Rep. 2018. https://​doi.​org/​10.​15252/​embr.​201845809 Demonstrates the importance of YAP and TAZ on cancer initiation and specifically the role of YAP on epithelial-to-mesenchymal transition, suggesting that these can be targetable drugs.
38.
Zurück zum Zitat Chan JW, Yeh I, El-Sayed IH, Algazi AP, Glastonbury CM, Ha PK, et al. Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. Head Neck. 2019;41:E82–5.CrossRef Chan JW, Yeh I, El-Sayed IH, Algazi AP, Glastonbury CM, Ha PK, et al. Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. Head Neck. 2019;41:E82–5.CrossRef
39.
Zurück zum Zitat Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20:6582–92.PubMedPubMedCentralCrossRef Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20:6582–92.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat • García-Sancha N, Corchado-Cobos R, Pérez-Losada J, Cañueto J. MicroRNA dysregulation in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20092181 Excellent review on the role of microRNA in the development and spread of Cutaneous Squamous Cell Carcinoma including informative diagrams by experts in this topic.PubMedCentralCrossRef • García-Sancha N, Corchado-Cobos R, Pérez-Losada J, Cañueto J. MicroRNA dysregulation in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019. https://​doi.​org/​10.​3390/​ijms20092181 Excellent review on the role of microRNA in the development and spread of Cutaneous Squamous Cell Carcinoma including informative diagrams by experts in this topic.PubMedCentralCrossRef
42.
Zurück zum Zitat Yu X, Li Z. The role of miRNAs in cutaneous squamous cell carcinoma. J Cell Mol Med. 2016;20:3–9.PubMedCrossRef Yu X, Li Z. The role of miRNAs in cutaneous squamous cell carcinoma. J Cell Mol Med. 2016;20:3–9.PubMedCrossRef
43.
Zurück zum Zitat Wang A, Landén NX, Meisgen F, Lohcharoenkal W, Ståhle M, Sonkoly E, et al. MicroRNA-31 is overexpressed in cutaneous squamous cell carcinoma and regulates cell motility and colony formation ability of tumor cells. PLoS One. 2014;9:e103206.PubMedPubMedCentralCrossRef Wang A, Landén NX, Meisgen F, Lohcharoenkal W, Ståhle M, Sonkoly E, et al. MicroRNA-31 is overexpressed in cutaneous squamous cell carcinoma and regulates cell motility and colony formation ability of tumor cells. PLoS One. 2014;9:e103206.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Toll A, Salgado R, Espinet B, Díaz-Lagares A, Hernández-Ruiz E, Andrades E, et al. MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression. Mol Cancer. 2016;15:53.PubMedPubMedCentralCrossRef Toll A, Salgado R, Espinet B, Díaz-Lagares A, Hernández-Ruiz E, Andrades E, et al. MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression. Mol Cancer. 2016;15:53.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Mizrahi A, Barzilai A, Gur-Wahnon D, et al. Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes. Oncogene. 2018;37:218–30.PubMedCrossRef Mizrahi A, Barzilai A, Gur-Wahnon D, et al. Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes. Oncogene. 2018;37:218–30.PubMedCrossRef
47.
Zurück zum Zitat •• Robinson DJ, Patel A, Purdie KJ, et al. Epigenetic regulation of iASPP-p63 feedback loop in cutaneous squamous cell carcinoma. J Invest Dermatol. 2019;139:1658–1671.e8 Highlights the importance of epithelial-to-mesenchymal transition among the pleiotropic influences of p63 and its epigenetic regulation.PubMedCrossRef •• Robinson DJ, Patel A, Purdie KJ, et al. Epigenetic regulation of iASPP-p63 feedback loop in cutaneous squamous cell carcinoma. J Invest Dermatol. 2019;139:1658–1671.e8 Highlights the importance of epithelial-to-mesenchymal transition among the pleiotropic influences of p63 and its epigenetic regulation.PubMedCrossRef
48.
Zurück zum Zitat Kadota K, Nitadori J, Rekhtman N, Jones DR, Adusumilli PS, Travis WD. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. Am J Surg Pathol. 2015;39:1170–80.PubMedPubMedCentralCrossRef Kadota K, Nitadori J, Rekhtman N, Jones DR, Adusumilli PS, Travis WD. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. Am J Surg Pathol. 2015;39:1170–80.PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Smirnov A, Anemona L, Novelli F, Piro CM, Annicchiarico-Petruzzelli M, Melino G, et al. p63 is a promising marker in the diagnosis of unusual skin cancer. Int J Mol Sci. 2019;20:5781.PubMedCentralCrossRef Smirnov A, Anemona L, Novelli F, Piro CM, Annicchiarico-Petruzzelli M, Melino G, et al. p63 is a promising marker in the diagnosis of unusual skin cancer. Int J Mol Sci. 2019;20:5781.PubMedCentralCrossRef
50.
Zurück zum Zitat Matin RN, Chikh A, Chong SLP, et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med. 2013;210:581–603.PubMedPubMedCentralCrossRef Matin RN, Chikh A, Chong SLP, et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med. 2013;210:581–603.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Hu W-M, Jin J-T, Wu C-Y, Lu J-B, Zhang L-H, Zeng J, et al. Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience. Diagn Pathol. 2019;14:128.PubMedPubMedCentralCrossRef Hu W-M, Jin J-T, Wu C-Y, Lu J-B, Zhang L-H, Zeng J, et al. Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience. Diagn Pathol. 2019;14:128.PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Romano R-A Novel genetic models to study the role of DNp63 in squamous cell carcinoma. Romano R-A Novel genetic models to study the role of DNp63 in squamous cell carcinoma.
54.
Zurück zum Zitat Chikh A, Matin RNH, Senatore V, et al. iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. EMBO J. 2011;30:4261–73.PubMedPubMedCentralCrossRef Chikh A, Matin RNH, Senatore V, et al. iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. EMBO J. 2011;30:4261–73.PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Oh J-E, Kim RH, Shin K-H, Park N-H, Kang MK. DeltaNp63α protein triggers epithelial-mesenchymal transition and confers stem cell properties in normal human keratinocytes. J Biol Chem. 2011;286:38757–67.PubMedPubMedCentralCrossRef Oh J-E, Kim RH, Shin K-H, Park N-H, Kang MK. DeltaNp63α protein triggers epithelial-mesenchymal transition and confers stem cell properties in normal human keratinocytes. J Biol Chem. 2011;286:38757–67.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Zhao W, Wang H, Han X, et al. ΔNp63α attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma. Tumour Biol. 2016;37:10621–32.PubMedCrossRef Zhao W, Wang H, Han X, et al. ΔNp63α attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma. Tumour Biol. 2016;37:10621–32.PubMedCrossRef
59.
Zurück zum Zitat Yuen WY, Jonkman MF. Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: report of 7 cases and a review of the literature. J Am Acad Dermatol. 2011;65:780–9.PubMedCrossRef Yuen WY, Jonkman MF. Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: report of 7 cases and a review of the literature. J Am Acad Dermatol. 2011;65:780–9.PubMedCrossRef
60.
Zurück zum Zitat Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel). 2015;7:2443–58.CrossRef Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel). 2015;7:2443–58.CrossRef
61.
Zurück zum Zitat Martins VL, Vyas JJ, Chen M, Purdie K, Mein CA, South AP, et al. Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci. 2009;122:1788–99.PubMedPubMedCentralCrossRef Martins VL, Vyas JJ, Chen M, Purdie K, Mein CA, South AP, et al. Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci. 2009;122:1788–99.PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Li XM, Kim SJ, Hong D-K, Jung KE, Choi CW, Seo Y-J, et al. KLF4 suppresses the tumor activity of cutaneous squamous cell carcinoma (SCC) cells via the regulation of SMAD signaling and SOX2 expression. Biochem Biophys Res Commun. 2019;516:1110–5.PubMedCrossRef Li XM, Kim SJ, Hong D-K, Jung KE, Choi CW, Seo Y-J, et al. KLF4 suppresses the tumor activity of cutaneous squamous cell carcinoma (SCC) cells via the regulation of SMAD signaling and SOX2 expression. Biochem Biophys Res Commun. 2019;516:1110–5.PubMedCrossRef
63.
Zurück zum Zitat Sun F, Hu K. Krüppel-like factor 4 inhibits the transforming growth factor-β1-promoted epithelial-to-mesenchymal transition via downregulating plasminogen activator inhibitor-1 in lung epithelial cells. Dis Markers. 2015;2015:473742.PubMedPubMedCentral Sun F, Hu K. Krüppel-like factor 4 inhibits the transforming growth factor-β1-promoted epithelial-to-mesenchymal transition via downregulating plasminogen activator inhibitor-1 in lung epithelial cells. Dis Markers. 2015;2015:473742.PubMedPubMedCentral
64.
Zurück zum Zitat Zhang Q-L, Li XM, Lian D-D, Zhu MJ, Yim S-H, Lee J-H, et al. Tumor suppressive function of NQO1 in cutaneous squamous cell carcinoma (SCC) cells. Biomed Res Int. 2019;2019:2076579.PubMedPubMedCentral Zhang Q-L, Li XM, Lian D-D, Zhu MJ, Yim S-H, Lee J-H, et al. Tumor suppressive function of NQO1 in cutaneous squamous cell carcinoma (SCC) cells. Biomed Res Int. 2019;2019:2076579.PubMedPubMedCentral
65.
Zurück zum Zitat Zhou S, da Silva SD, Siegel PM, Philip A. CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro. Sci Rep. 2019;9:16317.PubMedPubMedCentralCrossRef Zhou S, da Silva SD, Siegel PM, Philip A. CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro. Sci Rep. 2019;9:16317.PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Cantariño N, Fernández-Figueras MT, Valero V, Musulén E, Malinverni R, Granada I, et al. A cellular model reflecting the phenotypic heterogeneity of mutant HRAS driven squamous cell carcinoma. Int J Cancer. 2016;139:1106–16.PubMedCrossRef Cantariño N, Fernández-Figueras MT, Valero V, Musulén E, Malinverni R, Granada I, et al. A cellular model reflecting the phenotypic heterogeneity of mutant HRAS driven squamous cell carcinoma. Int J Cancer. 2016;139:1106–16.PubMedCrossRef
68.
69.
Zurück zum Zitat Bordignon P, Bottoni G, Xu X, et al. Dualism of FGF and TGF-β signaling in heterogeneous cancer-associated fibroblast activation with ETV1 as a critical determinant. Cell Rep. 2019;28:2358–2372.e6.PubMedPubMedCentralCrossRef Bordignon P, Bottoni G, Xu X, et al. Dualism of FGF and TGF-β signaling in heterogeneous cancer-associated fibroblast activation with ETV1 as a critical determinant. Cell Rep. 2019;28:2358–2372.e6.PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Sasaki K, Sugai T, Ishida K, Osakabe M, Amano H, Kimura H, et al. Analysis of cancer-associated fibroblasts and the epithelial-mesenchymal transition in cutaneous basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. Hum Pathol. 2018;79:1–8.PubMedCrossRef Sasaki K, Sugai T, Ishida K, Osakabe M, Amano H, Kimura H, et al. Analysis of cancer-associated fibroblasts and the epithelial-mesenchymal transition in cutaneous basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. Hum Pathol. 2018;79:1–8.PubMedCrossRef
71.
Zurück zum Zitat Hernández-Ruiz E, Hernández-Muñoz I, Masferrer E, Ferrándiz-Pulido C, Andrades E, Gimeno J, et al. A myxoid fibrotic reaction pattern is associated with metastatic risk in cutaneous squamous cell carcinoma. Acta Derm Venereol. 2019;99:89–94.PubMed Hernández-Ruiz E, Hernández-Muñoz I, Masferrer E, Ferrándiz-Pulido C, Andrades E, Gimeno J, et al. A myxoid fibrotic reaction pattern is associated with metastatic risk in cutaneous squamous cell carcinoma. Acta Derm Venereol. 2019;99:89–94.PubMed
72.
Zurück zum Zitat Saenz-Sardà X, Carrato C, Pérez-Roca L, Puig L, Ferrándiz C, Ariza A, et al. Epithelial-to-mesenchymal transition contributes to invasion in squamous cell carcinomas originated from actinic keratosis through the differentiated pathway, whereas proliferation plays a more significant role in the classical pathway. J Eur Acad Dermatol Venereol. 2018;32:581–6.PubMedCrossRef Saenz-Sardà X, Carrato C, Pérez-Roca L, Puig L, Ferrándiz C, Ariza A, et al. Epithelial-to-mesenchymal transition contributes to invasion in squamous cell carcinomas originated from actinic keratosis through the differentiated pathway, whereas proliferation plays a more significant role in the classical pathway. J Eur Acad Dermatol Venereol. 2018;32:581–6.PubMedCrossRef
73.
76.
Zurück zum Zitat Geng S, Guo Y, Wang Q, Li L, Wang J. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma. Arch Dermatol Res. 2013;305:35–47.PubMedCrossRef Geng S, Guo Y, Wang Q, Li L, Wang J. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma. Arch Dermatol Res. 2013;305:35–47.PubMedCrossRef
77.
Zurück zum Zitat Xie S-L, Fan S, Zhang S-Y, et al. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway. Int J Cancer. 2018;142:1252–65.PubMedCrossRef Xie S-L, Fan S, Zhang S-Y, et al. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway. Int J Cancer. 2018;142:1252–65.PubMedCrossRef
78.
Zurück zum Zitat Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18:128–34.PubMedCrossRef Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18:128–34.PubMedCrossRef
79.
Zurück zum Zitat Toll A, Masferrer E, Hernández-Ruiz ME, Ferrandiz-Pulido C, Yébenes M, Jaka A, et al. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases. J Dermatol Sci. 2013;72:93–102.PubMedCrossRef Toll A, Masferrer E, Hernández-Ruiz ME, Ferrandiz-Pulido C, Yébenes M, Jaka A, et al. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases. J Dermatol Sci. 2013;72:93–102.PubMedCrossRef
Metadaten
Titel
The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma
Epithelial-to-Mesenchymal Transition in Cutaneous SCC
verfasst von
Maria-Teresa Fernandez-Figueras, MD, PhD
Luis Puig, MD, PhD
Publikationsdatum
01.06.2020
Verlag
Springer US
Erschienen in
Current Treatment Options in Oncology / Ausgabe 6/2020
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-020-00735-x

Weitere Artikel der Ausgabe 6/2020

Current Treatment Options in Oncology 6/2020 Zur Ausgabe

Skin Cancer (T Ito, Section Editor)

Current Treatment of Melanoma Brain Metastasis

Neuroendocrine Cancers (JR Strosberg, Section Editor)

Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms

Neuroendocrine Cancers (JR Strosberg, Section Editor)

Hereditary Syndromes in Neuroendocrine Tumors

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.